Revance Therapeutics, Inc. - stock earnings
RVNC Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -55.7 million USD | 69.8 million USD |
| 2023Q3 | -141.2 million USD | 56.8 million USD |
| 2023Q2 | -67.3 million USD | 58.1 million USD |
| 2023Q1 | -66.1 million USD | 49.3 million USD |
| 2022Q4 | -144.6 million USD | 49.9 million USD |
| 2022Q3 | -84.7 million USD | 29.0 million USD |
| 2022Q2 | -61.5 million USD | 28.4 million USD |
| 2022Q1 | -64.4 million USD | 25.3 million USD |
| 2021Q4 | -63.1 million USD | 26.0 million USD |
| 2021Q3 | -74.4 million USD | 19.7 million USD |
| 2021Q2 | -72.2 million USD | 18.8 million USD |
| 2021Q1 | -71.6 million USD | 13.3 million USD |
| 2020Q4 | -78.3 million USD | 11.1 million USD |
| 2020Q3 | -81.3 million USD | 3.8 million USD |
| 2020Q2 | -60.6 million USD | 299000 USD |
| 2020Q1 | -61.9 million USD | 58000 USD |
| 2019Q4 | -45.3 million USD | 89000 USD |
| 2019Q3 | -41.4 million USD | 46000 USD |
| 2019Q2 | -37.4 million USD | ? USD |
| 2019Q1 | -35.3 million USD | 278000 USD |
| 2018Q4 | -40.6 million USD | 487000 USD |
| 2018Q3 | -32.8 million USD | 2.4 million USD |
| 2018Q2 | -34.1 million USD | 686000 USD |
| 2018Q1 | -35.0 million USD | 193000 USD |
| 2017Q4 | -35.9 million USD | 37000 USD |
| 2017Q3 | -30.7 million USD | 75000 USD |
| 2017Q2 | -26.9 million USD | 75000 USD |
| 2017Q1 | -27.2 million USD | 75000 USD |
| 2016Q4 | -26.8 million USD | 75000 USD |
| 2016Q3 | -18.0 million USD | 75000 USD |
| 2016Q2 | -24.6 million USD | 75000 USD |
| 2016Q1 | -19.9 million USD | 75000 USD |
| 2015Q4 | -22.1 million USD | 75000 USD |
| 2015Q3 | -19.2 million USD | 75000 USD |
| 2015Q2 | -16.8 million USD | 75000 USD |
| 2015Q1 | -15.4 million USD | 75000 USD |
| 2014Q4 | -14.2 million USD | 75000 USD |
| 2014Q3 | -14.0 million USD | 75000 USD |
| 2014Q2 | -13.3 million USD | 75000 USD |
| 2014Q1 | -21.4 million USD | 158000 USD |
| 2013Q4 | -10.1 million USD | 309000 USD |
| 2013Q3 | -8.9 million USD | 158000 USD |
| 2013Q2 | -11.8 million USD | 75000 USD |
| 2013Q1 | -21.7 million USD | 75000 USD |
| 2012Q4 | -10.9 million USD | 117000 USD |
| 2011Q4 | ? USD | 557000 USD |
RVNC Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -324.0 million USD | 234.0 million USD |
| 2022 | -356.4 million USD | 132.6 million USD |
| 2021 | -286.8 million USD | 77.8 million USD |
| 2020 | -282.1 million USD | 15.3 million USD |
| 2019 | -156.2 million USD | 413000 USD |
| 2018 | -142.6 million USD | 3.7 million USD |
| 2017 | -120.6 million USD | 262000 USD |
| 2016 | -89.3 million USD | 300000 USD |
| 2015 | -73.5 million USD | 300000 USD |
| 2014 | -62.9 million USD | 383000 USD |
| 2013 | -52.4 million USD | 617000 USD |
| 2012 | -58.3 million USD | 717000 USD |
| 2011 | -44.9 million USD | 557000 USD |
RVNC
Price: $3.80
52 week price:
Earnings Per Share: -3.83 USD
P/E Ratio: -1.12
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 728800
Ebitda: -30.2 millionMarket Capitalization: 413.7 million